A series of new biosynthetic derivatives of tallysomycins A and B were obtained by precursor amine-feeding fermentation.
and BRADNER et al. 6, 7) . The mechanism of action, [8] [9] [10] toxicity11,12) and pharmacokineticsl3.14) of tallysomycin A have been studied. The 13C NMR assignments of tallysomycin A were recently described by GREENAWAY et al.1n).
It has been reported16) that, in the bleomycin fermentation, certain amines added to the fermentation medium were incorporated into the terminal amine moiety of bleomycin molecule, affording new bleomycin derivatives. Addition of a variety of diamines to the tallysomycin fermentation medium resulted in the formation of two series of new tallysomycin derivatives, both containing the precursor amine Tallysomycin A B * The USAN generic name " Talisomycin" has been assigned to tallysomycin A. VOL. XXXIV NO. 6 THE JOURNAL OF ANTIBIOTICS in the terminal position but differing in the presence or absence of a 19-lysine moiety in the subterminal position. The new biosynthetic tallysomycin derivatives are designated as tallysomycin S, followed by a suffix number to distinguish the terminal amine moiety and a suffix letter of "a" or "b" to show whether it is the analog of tallysomycin A or B (i.e. the presence or absence of 13-lysine moiety).
This paper reports the production, isolation and characterization of a series of biosynthetic tallysomycin derivatives. The antimicrobial and antitumor activities of the new derivatives are also described.
Materials and Methods

Precursor Amines
The precursor amine compounds used in the present study are listed in Table 1 . Most of the amines tested were commercially available except for N-(a-phenylethyl)-1,3-diaminopropane and 3-aminopropyldimethylsulfonium chloride, which were prepared in our laboratories according to published method. 17, 18) Fermentation An agar slant of Streptoalloteichus hindustanus strain E465-94 (ATCC 31158) was used to inoculate vegetative medium containing 1.5 % glucose, 0.2 % yeast extract, 0.5 % peptone, 0.05 % K2HPO4, 0.05 % MgSO4 -7H2O and 0.5% CaCO3, the pH being adjusted to 7.2 before sterilization. The seed culture was incubated at 28°C for 48 hours on a rotary shaker (250 rpm), and 10 ml of the growth was transferred to a 500-m1 Erlenmeyer flask containing 100 ml of the fermentation medium composed of 2.5 % sucrose, 0.5% glucose, 3 % cottonseed meal, 3 % distiller's solubles, 0.3% (NH4)2SO4, 0.003% ZnSO4 • 7H2O, 0.01 % CuSO4 • 5H2O and 0.4 % CaCO3. A precursor amine compound was added to the medium in the form of a neutralized aqueous solution at concentrations of 0.1 -0.2 % (w/v). The pH of the fermentation medium was adjusted to pH 6.5 before sterilization. Antibiotic production in shake cultures generally reached a maximum after 5-6 days at 28°C.
Assay of Antibacterial Activity Antibiotic levels in fermentation broths and the extracts of tallysomycin derivatives were determined by a paper disc-agar diffusion method using Mycobacterium smegmatis strain M6-3 as the test organism. This is a laboratory-developed aminoglycoside-resistant mutant derived from M. smegmatis ATCC 607. It is insensitive to nebramycin factors which are generally co-produced1) with tallysomycin. Tallysomycin A hydrochloride was used as the assay standard, the potency of copper-free tallysomycin A free base being defined as 1,000 units/mg. Test and standard samples were diluted with M/15 phosphate buffer of pH 7.0.
Isolation and Purification
Harvested broth was filtered with filter aid and the bioactivity in the filtrate adsorbed on a column of Amberlite IRC-50 (60% NH,+ form) at pH 7.0. The column was washed with water and then developed with 0.1 N hydrochloric acid. The active fractions were collected, neutralized with aqueous ammonia and adsorbed on a column of activated charcoal. The charcoal was washed with water and tallysomycin eluted with a 1: 1 mixture of n-butanol and diluted HCl solution (pH 2.0). The butanol layer was separated, and the aqueous layer was neutralized with Amberlite IR-45 (OH-form) and concentrated in vacuo. The aqueous concentrate was added to 5 % CuCl2 solution and applied on a column of Diaion HP-20. The column was developed with water, and the active eluate was concentrated in vacuo and lyophilized to give a blue powder of tallysomycin complex in a copper-chelated form. The antibiotic complex thus obtained was separated by CM-Sephadex C-25 column chromatography using increasing concentrations of aqueous ammonium formate solution (1 -7 %). The fractions were monitored by bioassay as well as by optical density at 290 nm. Each component was further purified by desalting on a column of Diaion HP-20.
Identification of New Tallysomycin Derivatives
The purity and identity of tallysomycin derivatives was examined by thin-layer chromatography (TLC) using a silica gel plate (Kiesel gel 60F254, Merck) and a solvent system of MeOH -10% AcONH4= 
S11a,S11b
Sl2b S14b S13h S14a 1: 1 (S-102) or MeOH -10% AcONH4 -10% NH4OH=10: 9: 1 (S-123). Detection was made by a dual-wavelength TLC scanner (Shimadzu CS-910) at 290 nm. High-performance liquid chromatography (HPLC) was also employed to identify new biosynthetic tallysomycins. The HPLC apparatus used was a Model ALC204 of Waters Associates equipped with a Type U6K injector and a Model 440 UV-detector operating at 254 nm. A column of h Bondapak C18 (Waters, 300 x 4 mm I.D.) was used.
The mobile phase was a 30 % aqueous acetonitrile solution containing PIC reagent B-7 (Waters).
The flow rate was 1.0 ml/minute under a pressure of 800 p.s.i. The sample size injected was 1 tol of 2 mg/ml solution.
For the identification of the terminal amine moiety of tallysomycins, each component was hydrolyzed with 6 N HCl at 105°C for 17 hours and the amine or amino acid liberated in the hydrolyzate was examined by TLC using systems S-102 and S-123. The presence or absence of 13-lysine in the hydrolyzate was also determined simultaneously.
Determination of Antimicrobial Activity
The minimum inhibitory concentrations (MIC) of tallysomycin derivatives were determined against Gram-positive, Gram-negative, acid-fast bacteria and fungi by a two-fold agar dilution method using a
Steer's multiple inoculator. Nutrient agar was used for bacteria and SABOURAUD agar for fungi. The ability to induce prophage in a lysogenic bacterium, E. cola W1709 (2), was determined according to the method of LEIN et a1. 19) . Plaque counts were made on agar plates containing the test compound (T) and on control plates (C). A T/C ratio of the plaque counts of greater than 3.0 was considered significant and the lysogenic induction activity (ILB activity) was expressed as the minimum inducible concentration of the test compound. Physico-chemical The antitumor activity of tallysomycin derivatives was examined in three experimental tumor systems in mice. Lymphocytic leukemia P388 was implanted into the peritoneum of BDF1 mice of either sex at an inoculum size of 3 x 105 cells per mouse. Sarcoma 180 ascites tumor was inoculated intraperitoneally into male dd-strain mice with 2.5 x 106 cells per mouse. Melanotic melanoma B16 was implanted subcutaneously into BDF1 mice using 5 x 105 cells per mouse.
Twenty-four hours after the implantation of tumor cells, graded doses of test compounds were administered to mice intraperitoneally in an injection volume of 0.2 ml per 10 g of body weight. Test compounds were given once daily for 9 days (rid 1-9 schedule). Death or survival of the treated and non-treated (control) animals was recorded daily during the observation period of 45 days after the implantation of tumor cells, and the median survival time was calculated for each of the test (T) and control (C) groups. A T/C value equal to or greater than 125 % against leukemia P388 was considered to be a significant antitumor effect. The actual dose giving a T/C of 125 % was estimated by linear regression analysis and defined as the effective dose 125 or ED125. The effective dose 150 (ED150) was employed for the evaluation of antitumor effect against sarcoma 180. In the B16 melanoma experiment the tumor size was measured on day 16 after tumor inoculation, and the dose giving 50% inhibition of tumor growth (ID50) was calculated from regression lines.
Acute Toxicity Determination Graded doses of tallysomycin derivatives were administered intraperitoneally to groups of dd mice. Death or survival of the animals was recorded for 30 days and the LD50 (median lethal dose) was calculated according to the method of VAN DER WAERDEN.20) 
Results and Discussion
A number of new tallysomycin derivatives were produced when certain diamines were added to the fermentation medium.
Under the fermentation conditions used in the present study, tallysomycin B derivatives (Sb series) were produced more predominantly than those of tallysomycin A (Sa series). In some cases only the former type of analog was obtained. Tallysomycins A and B were coproduced as minor components in the precursor-fed fermentation. Table 1 shows the biosynthetic tallysomycin derivatives isolated along with the structure of terminal amine moiety. The physico-chemical properties of tallysomycin derivatives are listed in Table 2 .
The antimicrobial activities of tallysomycin derivatives determined by means of a serial agar dilution method are shown in Table 3 . They were active against Gram-positive, Gram-negative and acidfast bacteria. A fungal strain, Aspergillus fumigatus, was inhibited at low concentrations of all derivatives except for tallysomycins S12b, S13b and S14b. The new tallysomycin derivatives showed the ability to induce prophage of lysogenic bacteria as is shown in Table 3 .
The antitumor activities of tallysomycin derivatives determined in three tumor systems are shown in Table 4 . The acute toxicities of tallysomycin derivatives for mice after a single intraperitoneal admini- Table 4 . Antitumor activity and acute toxicity of tallysomycin derivatives. 
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